Objective To investigate the clinical value of peri-interventional procedure serum bile acid(TBA)detection in patients with primary liver cancer. Methods The serum TBA was examined peri-operatively in 160 patients with primary liver cancer for testing the correlations between TBA, liver function, the degree of hepatocirrhosis, interventional therapy method and hepatic failure. Results The preoperative mean value of serum TBA incseased significantly in comparing with that of the control group (P

Objective To study the protective effects of ?-asarone against the myocardial ischemia/ reperfusion injury (MI/RI) in cultured cardiac myocytes. Methods MI/RI model was set up with Na2S2O4, which make use of rat cardiac myocytes. The viability of cardiac myocytes (using MTT method), dehydrogenase (LDH, CK) activitices in the medium were measured. Results In MI/RI model, ?-asarone can obviously advance the viability of cardiac myocytes, and decrease the dehydrogenase (LDH, CK) activitices in the medium. Conclusion ?-asarone showed protective effects against the myocardial ischemia/reperfusion injury in cultured cardiac myocytes.

Objective To design and prepare recombinant mutant human high mobility group box 1 protein (HMGB1s) that can combine with HMGB1 receptors but cannot produce inflammatory effect, and accordingly lead to the creation of a new potential agent for anti-inflammatory therapy. Methods This experiment was based on successful clone and expression of human HMGB1.Six mutant HMGB1 cDNA were designed and constructed by one step inverse PCR. They were cloned into prokaryotic expressive vector pQE80L and followed with production of mutant HMGB1s and identification by Western blotting. Results Six mutant proteins were designed and constructed into prokaryotic expressive vector pQE80L. The recombinant HMGB1 proteins were obtained and identified by Western blotting. Conclusion Human HMGB1 mutants have been successfully constructed and the expression and characterization of intent proteins are identified. It will lay a foundation for further study on biological functions of HMGB1.

Objective To study the protective effects of ?-asarone on PC12 cells damage induced by Glutamate. Method The effects of ?-asarone on PC12 cells after Glutamate intoxication on morphology, extent of damage, livability, intracellular calcium concentration and apoptosis ratio were observed. Result Morphological changes, LDH leakage and intracellular calcium concentration increasing, and cell survival decreasing were observed in PC12 cells exposured to Glutamate. 7.5, 15, 30 ?g/mL?-asarone can increase cell survival, decrease LDH leakage. 15, 30 ?g/mL ?-asarone can reduce intracellular calcium concentration and apoptosis ratio. Conclusion ?-asarone prevents the toxicity of Glutamate, and it maybe attribute to its effect of anticalcium.

Objective To study the effects of ?-asarone on mitochondrial membrane potential(MMP) of cardiac myocytes with ischemia reperfusion injury. Methods The cardiac myocytes model of myocardial ischemia reperfusion injury (MIRI) was induced with sodium dithionite (Na2S2O4). The primary cultured cardiac myocytes of SD neonatal rats were randomized into six groups:normal group,model control group,high-dose ?-asarone (25 ?g/mL),middle-dose ?-asarone group(12.5 ?g/mL),low-dose ?-asarone group (6.25 ?g/mL) and medium group. Mitochondrial membrane potential(MMP) of myocardial cells were measured by flow cytometry. Results Compared with the normal group,MMP in the model control group was obviously decreased(P

Objective To analyze the clinical and pathologieal characteristics of IgA nephmlogy secondary to primary sj(o)gren's syndrome(pSS).Method The clinical and pathological data of 8 patients with pSS and IgA in Changzheng Hospital from 2004 to 2009 were analyzed.Results The average age of seven female and one male was (44±8) years old.Five patients presented with edema and proteinuria.Eight patients presented with microhematuria.The average 24-hour proteinuria was (3±4) g.Two patients had hypertension.Serum creatinine levels of two patients were higher than normal level,the others'were normal.Light microscopy examination showed three patients were mild mesangial proliferation with Lee's classification grade Ⅰ;five patients had global sclerosis with Lee's classification grade Ⅱ,Ⅲ and Ⅳ.Positive IgA was mainly found under immunofluorescence microscopy.Electronic microscopy showed no electron-dense deposits.Conclusion IgA nephrology secondary to pSS is different from primary IgA nephrology under immunofluorescence microscopy.

Objective To explore the effectiveness and esophageal strictures of concurrent chemoradiotherapy in patients with cervical and upper-thoracic esophageal cancer (EC) and middle-thoracic and lower-thoracic EC.Methods Between January 2011 and December 2014,ninety patients with different parts of EC were treated with radiotherapy combined with concurrent chemotherapy in People's Hospital of Subei.The median irradiation dose was 60 Gy.The chemotherapy regimens consisted of Paclitaxel and Nedaplatin.Of all the patients,48 patients had cervical and upper-thoracic EC,42 patients had middle-thoracic and lowerthoracic EC.The response rates,the local control rates,the survival rates and esophageal strictures were evaluated between two groups.Results The follow-up rate was 100％.The response rates of the patients with cervical and upper-thoracic EC and middle-thoracic and lower-thoracic EC were 81.2％ and 73.8％ (x2 =0.717,P =0.397),respectively.The 1-year local control rates of the patients with cervical and upper-thoracic EC and middle-thoracic and lower-thoracic EC were 90.3％ and 71.8％ (x2 =5.865,P =0.015),respectively.The 1-year survival rates of the patients with cervical and upper-thoracic EC and middle-thoracic and lower-thoracic EC were 87.5％ and 69.0％ (x2 =4.580,P =0.032),respectively.The moderate-to-severe esophageal strictures rates of the patients with cervical and upper-thoracic EC and middle-thoracic and lower-thoracic EC were 55.6％ and 29.4％ (x2 =5.360,P =0.021),respectively.There were no significant differences in shortterm effects between the cervical and upper-thoracic EC and middle-thoracic and lower-thoracic EC.The patients with cervical and upper-thoracic EC showed significantly higher 1-year local control rates,1-year survival rates and esophageal strictures rates than those with middle-thoracic and lower-thoracic EC.Conclusion The effectiveness of concurrent chemoradiotherapy is better in the patients with cervical and upper-thoracic EC than in those with middle-thoracic and lower-thoracic EC,but the esophageal stenosis is more severe in the patients with cervical and upper-thoracic EC than in those with middle-thoracic and lower-thoracic EC.

Objective: To study the treatment of experimental lung metastasis by intratracheal injection of IL 18 gene recombinant adenovirus. Methods: (1)The mouse IL 18 mRNA was detected by RT PCR, the concentrations of IL 18, associated cytokines in lung lavage and blood were determined by ELISA at different times after intratracheal injection of IL 18 recombinant adenovirus. (2)The lung metastasis nodes, mouse survival period, survival rates were investigated in the treatment of experimental lung metastasis in C57BL/6 mouse model. The NK activity and CTL activity were determined by 51 Cr 4 h release method. Results: (1)The IL 18 mRNA could be detected in lung tissue 6 h after intratracheal use of IL 18 recombinant adenovirus, and the concentrations of IL 18 in lung lavage was higher than that of peripheral blood, and both IL 18 mRNA and IL 18 could not be detected in control groups. (2)Intratracheal use of IL 18 recombinant adenovirus had significant therapeutic effect on experimental lung metastasis with the results of increased CTL and NK activity, and with longer survival period and higher survival rates compared with the control groups. Conclusion: Intratracheal usage of adenovirus vector containing IL 18 gene has therapeutic effect on the lung metastasis, denoting that gene therapy of lung diseases can be done through airway directly with recombinant adenovirus.

Objective To observe the efficacy of ealcitonin and bisphosphonates on renal osteopathy of maintenance hemodialysis (MHD)patients. Methods Forty-three MHD patients were raindomly divided into two groups: A group and B group. All the patients were routinely received oral calcium carbonate 1.0 g tid and calcitriol 0.25 μg qd. Calcitonin (20U) hypodermic injection was given three times a week additionally during hemodialysis in A group. Patients in B group received bisphosphonates 70 mg once a week based on the therapy of A group. Serum levels of intact parathyroid hormone (iPTH), calcium, phosphorus, alkaline phosphatase (AKP), bone mass density (BMD) of lumbar spine and femoral neck, and the degree of bone ache (visual analogue scale, VAS) were assessed before the therapy and 3, 6 and 12 months after treatment. The adverse reactions were recorded during treatment. Results The levels of AKP and iPTH in both two groups decreased significantly after treatment. The above values of pre-treatment and 12 months after treatment were as follows: AKP(U/L)of A group 244.05±41.99 and 148.35±27.71,of B group 245.60±40.86 and 143.40±28.03;PTH(ng/L) of A group 697.5±119.7 and 267.4±45.9,of B group 708.2±120.3 and 277.6±41.9 (all P<0.05). While the levels of calcium and phosphorus did not change obviously during treatment (P>0.05). BMD was not improved at 3, 6 mouths and became better at 12 mouths after treatment. As compared to pre-treatment, BMD of lumbar spine(g/cm2) in A group was 1.062±0.223 vs 1.202±0.251 ,in B group 1.033±0.152 vs 1.189±0.225; BMD of femoral neck (g/cm2)in A group was 0.993±0.108 vs 1.067±0.095,in B group 0.947±0.083 vs 1.018 ±0.217 (all P<0.05). The scores of VAS also decreased significantly at 3, 6, 12 months after treatment(P<0.05). No severe adverse reaction was found during the treatment. Conclusions Utilization of calcitonin and combination with bisphosphonates during bemodialysis can effectively preserve the BMD and prevent bone loss in MHD patients and is well tolerated. No significant difference of therapeutic effect is observed between using ealcitonin or combination with bisphosphonates.

Objective To assess the safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms.Methods Totally 31 patients who were treated using stent-assisted coil embolization were analyzed retrospectively.All the patients were divided into aspirin combined clopidogrel group (double resistance group,n=18) and tirofiban group (n=13).Tirofiban was injected after the stent was semi-released or released completely.The patients were followed-up after operation to assess whether the patient had a new infarction,stent patency and aneurysm embolization effect.One day before operation and 3 days after operation,platelet count and activated thromboplastin time (APTT) were detected respectively.Score Glasgow (GOS) was used to evaluate the clinical outcome of patients and the operative complications were recorded.Results A total of 34 aneurysms were found in 31 patients,and 32 aneurysms were treated.Urinary tract hemorrhage was founded in 1 case and recurrent aneurysms were founded in 7 cases after embolization.None of the patients developed thrombocytopenia,retroperitoneal and gastrointestinal bleeding related to tirofiban administration.There were no postoperative cerebral infarction and thrombosis events.GOS of 27 cases were ≥4.Platelet count and APTT 1 day before and 3 days after operation had no statistically significance between two groups (both P＞0.05).Conclusion It is safe and effective for tirofiban in stent-assisted aneurysm embolization and can be used as an alternative to the dual resistance.